Literature DB >> 3218659

Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein.

F Velasquez Forero1, N Garcia Prugue, N Ruiz Morales.   

Abstract

Twenty-six adult patients with idiopathic nephrotic syndrome, ages ranging from 16 to 62 years, were prospectively evaluated with selective renal venogram for the presence of renal vein thrombosis (RVT). Ten patients had membranoproliferative glomerulonephritis (MPGN); 5, membranous nephropathy (MGN); 3, diffuse proliferative glomerulonephritis (DGPG), and 1 focal glomerulonephritis (FPG). Renal vein thrombosis was observed in 11 patients. The primary nephropathies in these patients were: MPGN in 4, MGN in 3, FGS in 2, FPG in 1, and DGPG in 1. All patients were asymptomatic. The clinical and renal pathology features were similar in patients with and without RVT. Other thromboembolic complications were observed in 4 patients. In conclusion, renal vein thrombosis was observed in 42% of our patients and MPGN was the most frequent nephropathy associated with RVT.

Entities:  

Mesh:

Year:  1988        PMID: 3218659     DOI: 10.1159/000167654

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

1.  Venous thromboembolism in patients with membranous nephropathy.

Authors:  Sophia Lionaki; Vimal K Derebail; Susan L Hogan; Sean Barbour; Taewoo Lee; Michelle Hladunewich; Allen Greenwald; Yichun Hu; Caroline E Jennette; J Charles Jennette; Ronald J Falk; Daniel C Cattran; Patrick H Nachman; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

Review 2.  Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.

Authors:  Keattiyoat Wattanakit; Mary Cushman
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

3.  Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Authors:  Taewoo Lee; Andrea K Biddle; Sofia Lionaki; Vimal K Derebail; Sean J Barbour; Sameer Tannous; Michelle A Hladunewich; Yichun Hu; Caroline J Poulton; Shannon L Mahoney; J Charles Jennette; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Heather N Reich; Patrick H Nachman
Journal:  Kidney Int       Date:  2013-12-11       Impact factor: 10.612

Review 4.  Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.

Authors:  Bryce A Kerlin; Rose Ayoob; William E Smoyer
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

5.  Characteristics of patients diagnosed with renal vein thrombosis and glomerulopathy: a case series.

Authors:  Oliver Ross; Andrew Pourmoussa; Michael Batech; John J Sim
Journal:  Int Urol Nephrol       Date:  2016-10-28       Impact factor: 2.370

6.  Serum albumin and risk of venous thromboembolism.

Authors:  Aaron R Folsom; Pamela L Lutsey; Susan R Heckbert; Mary Cushman
Journal:  Thromb Haemost       Date:  2010-04-13       Impact factor: 5.249

7.  Pulmonary thrombosis as the first manifestation of systemic lupus erythematosus in a 14-year-old boy.

Authors:  Annie Harroche; Natascha Remus; Solenn Gaubicher; Olivier Dunand; Magali Colombat; Christophe Delacourt; Fouad Madhi
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

8.  Thromboembolic complications in childhood nephrotic syndrome: a clinical profile.

Authors:  Deepti Suri; Jasmina Ahluwalia; Akshay K Saxena; Kushaljit S Sodhi; Paramjeet Singh; Bhagwant R Mittal; Reena Das; Amit Rawat; Surjit Singh
Journal:  Clin Exp Nephrol       Date:  2013-12-18       Impact factor: 2.801

9.  Treatment of venous thrombosis at unusual sites.

Authors:  Robert D McBane; Waldemar E Wysokinski
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

10.  Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study.

Authors:  Sanjeev Kumar; Ananda Chapagain; Dorothea Nitsch; Muhammad M Yaqoob
Journal:  BMC Nephrol       Date:  2012-09-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.